The ability to identify-early in the course of therapy-patients that are not responding to a particular neoadjuvant regimen would provide the opportunity to switch to a potentially more efficacious treatment and transform current practice. Unfortunately, existing methods of determining early response are inadequate. The vision for this program is to develop tumor-forecasting methods for predicting response in individual breast cancer patients after a single cycle of neoadjuvant therapy. We propose to combine time-resolved drug- response cell scale data with physiological and tissue scale imaging data in order to initialize and constrain a multi-scale angiogenesis-cell proliferation model designed to predict both size and spatial characteristics of breast tumors at the completion of therapy. To achieve this goal, we will pursue the following specific aims: 1. (Pre-clinical validation) In the BT-474 HER2+ human breast cancer cell line, we will obtain: 1a. (cell scale) in vitro data quantifying rates of entry of proliferating cells into quiescence and apoptosis; 1b. (physiologica scale) in vivo MRI and PET measurements of cellularity, vascularity, and metabolism; 1c. (tissue scale) in vivo MR elastography measurements to quantify the tumor mechanical properties; 1d. (all scales) in situ data from fixed tumor tissue to corroborate cell and imaging-based metrics. These data will be integrated into the multi-scale model to predict tumor response after one cycle of the targeted anti-HER2 agents trastuzumab and lapatinib. 2. (Clinical application) In HER2+ patients receiving neoadjuvant trastuzumab and lapatinib, we will obtain: 2a. (physiological scale) in vivo MRI and PET measurements of cellularity, vascularity, and metabolism; 2b. (tissue scale) in vivo MR elastography measurements to quantify tumor mechanical properties. Guided by the results from Aim 1, these data will be integrated into the multi-scale model and make predictions on breast tumor response outcomes after a single cycle of trastuzumab and/or lapatinib. If successful, our approach would be the foundation for high-impact, large-scale application in clinical settings.

Public Health Relevance

We hypothesize that patient specific imaging data combined with an estimate of the effect of the neoadjuvant regimen on tumor cell phenotype, will enable a multi-scale model to accurately predict the response of breast tumors after a single cycle of therapy on an individual basis. Our goal is to provide the breast cancer community with a rigorous, practical method of predicting therapeutic response that is appropriate for incorporation into clinical trials and, ultimately, clinical practice.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
7U01CA174706-04
Application #
9071375
Study Section
Special Emphasis Panel (ZEB1-OSR-C (J2)S)
Program Officer
Zhang, Huiming
Project Start
2013-06-01
Project End
2019-08-31
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
4
Fiscal Year
2016
Total Cost
$211,784
Indirect Cost
$99,457
Name
University of Texas Austin
Department
Engineering (All Types)
Type
Schools of Engineering
DUNS #
170230239
City
Austin
State
TX
Country
United States
Zip Code
78712
Hormuth 2nd, David A; Weis, Jared A; Barnes, Stephanie L et al. (2018) Biophysical Modeling of In Vivo Glioma Response After Whole-Brain Radiation Therapy in a Murine Model of Brain Cancer. Int J Radiat Oncol Biol Phys 100:1270-1279
Paudel, B Bishal; Harris, Leonard A; Hardeman, Keisha N et al. (2018) A Nonquiescent ""Idling"" Population State in Drug-Treated, BRAF-Mutated Melanoma. Biophys J 114:1499-1511
Joint Head and Neck Radiotherapy-MRI Development Cooperative (2018) Dynamic contrast-enhanced magnetic resonance imaging for head and neck cancers. Sci Data 5:180008
Rocha, H L; Almeida, R C; Lima, E A B F et al. (2018) A HYBRID THREE-SCALE MODEL OF TUMOR GROWTH. Math Models Methods Appl Sci 28:61-93
Hormuth 2nd, David A; Eldridge, Stephanie L; Weis, Jared A et al. (2018) Mechanically Coupled Reaction-Diffusion Model to Predict Glioma Growth: Methodological Details. Methods Mol Biol 1711:225-241
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Jarrett, Angela M; Hormuth, David A; Barnes, Stephanie L et al. (2018) Incorporating drug delivery into an imaging-driven, mechanics-coupled reaction diffusion model for predicting the response of breast cancer to neoadjuvant chemotherapy: theory and preliminary clinical results. Phys Med Biol 63:105015
Jones, Zack W; Leander, Rachel; Quaranta, Vito et al. (2018) A drift-diffusion checkpoint model predicts a highly variable and growth-factor-sensitive portion of the cell cycle G1 phase. PLoS One 13:e0192087
Jarrett, Angela M; Lima, Ernesto A B F; Hormuth 2nd, David A et al. (2018) Mathematical models of tumor cell proliferation: A review of the literature. Expert Rev Anticancer Ther 18:1271-1286
Virostko, John; Hainline, Allison; Kang, Hakmook et al. (2018) Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted magnetic resonance imaging for predicting the response of locally advanced breast cancer to neoadjuvant therapy: a meta-analysis. J Med Imaging (Bellingham) 5:011011

Showing the most recent 10 out of 51 publications